Skip to main content

Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.

Publication ,  Journal Article
Akinyemiju, T; Moore, JX; Pisu, M; Goodman, M; Howard, VJ; Safford, M; Gilchrist, SC; Cushman, M; Long, L; Judd, SE
Published in: Oncotarget
August 6, 2019

This study examines the association between inflammatory biomarkers and risk of cancer mortality by race. Data were obtained from 1,856 participants in the prospective REGARDS cohort who were cancer-free at baseline, and analyzed in relation to cancer mortality prospectively. Biomarkers were log-transformed and categorized into tertiles due to non-normal distributions, and Cox proportional hazard regression models were utilized to compute hazard ratios with 95% confidence intervals using robust sandwich methods. Individuals in the highest tertile of IL-6 had over a 12-fold increased risk of cancer mortality (HR: 12.97, 95% CI: 3.46-48.63); those in the highest tertile of IL-8 had over a 2-fold increased risk of cancer mortality (HR: 2.21, 95% CI: 0.86-5.71), while those in the highest tertile of IL-10 had over a 3-fold increased risk of cancer mortality (HR: 3.06, 95% CI: 1.35-6.89). In race-stratified analysis, each unit increase in IL-6 was associated with increased risk of cancer mortality among African-Americans (HR: 3.88, 95% CI: 1.17-12.88) and Whites (5.25, 95% CI: 1.24-22.31). If replicated in larger, racially diverse prospective cohorts, these results suggest that cancer patients may benefit from clinical or lifestyle approaches to regulate systemic inflammation as a cancer prevention strategy.

Duke Scholars

Published In

Oncotarget

DOI

EISSN

1949-2553

Publication Date

August 6, 2019

Volume

10

Issue

47

Start / End Page

4857 / 4867

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Akinyemiju, T., Moore, J. X., Pisu, M., Goodman, M., Howard, V. J., Safford, M., … Judd, S. E. (2019). Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort. Oncotarget, 10(47), 4857–4867. https://doi.org/10.18632/oncotarget.27108
Akinyemiju, Tomi, Justin X. Moore, Maria Pisu, Michael Goodman, Virginia J. Howard, Monika Safford, Susan C. Gilchrist, Mary Cushman, LeAnn Long, and Suzanne E. Judd. “Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.Oncotarget 10, no. 47 (August 6, 2019): 4857–67. https://doi.org/10.18632/oncotarget.27108.
Akinyemiju T, Moore JX, Pisu M, Goodman M, Howard VJ, Safford M, et al. Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort. Oncotarget. 2019 Aug 6;10(47):4857–67.
Akinyemiju, Tomi, et al. “Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.Oncotarget, vol. 10, no. 47, Aug. 2019, pp. 4857–67. Pubmed, doi:10.18632/oncotarget.27108.
Akinyemiju T, Moore JX, Pisu M, Goodman M, Howard VJ, Safford M, Gilchrist SC, Cushman M, Long L, Judd SE. Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort. Oncotarget. 2019 Aug 6;10(47):4857–4867.

Published In

Oncotarget

DOI

EISSN

1949-2553

Publication Date

August 6, 2019

Volume

10

Issue

47

Start / End Page

4857 / 4867

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis